FR2505186A1 - Preparations a base de membranes cellulaires ou de cellules entieres de propionibacteries, utilisables notamment en cancerologie, et utilisation de propionibacteries pour obtenir ces preparations - Google Patents
Preparations a base de membranes cellulaires ou de cellules entieres de propionibacteries, utilisables notamment en cancerologie, et utilisation de propionibacteries pour obtenir ces preparations Download PDFInfo
- Publication number
- FR2505186A1 FR2505186A1 FR8109265A FR8109265A FR2505186A1 FR 2505186 A1 FR2505186 A1 FR 2505186A1 FR 8109265 A FR8109265 A FR 8109265A FR 8109265 A FR8109265 A FR 8109265A FR 2505186 A1 FR2505186 A1 FR 2505186A1
- Authority
- FR
- France
- Prior art keywords
- propionibacterium
- tumors
- mice
- granulosum
- preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 210000004027 cell Anatomy 0.000 title claims description 32
- 210000000170 cell membrane Anatomy 0.000 title claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 241001464975 Cutibacterium granulosum Species 0.000 claims abstract description 10
- 238000001959 radiotherapy Methods 0.000 claims abstract description 9
- 241001464974 Cutibacterium avidum Species 0.000 claims abstract description 8
- 229940055009 propionibacterium avidum Drugs 0.000 claims abstract description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 238000002512 chemotherapy Methods 0.000 claims description 16
- 239000000725 suspension Substances 0.000 claims description 14
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 7
- 239000010452 phosphate Substances 0.000 claims description 7
- 239000008363 phosphate buffer Substances 0.000 claims description 5
- 241000186427 Cutibacterium acnes Species 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229940055019 propionibacterium acne Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000872 buffer Substances 0.000 claims description 2
- 238000011360 adjunctive therapy Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 abstract description 61
- 241000186429 Propionibacterium Species 0.000 abstract description 9
- 230000004083 survival effect Effects 0.000 abstract description 9
- 230000001413 cellular effect Effects 0.000 abstract description 5
- 231100000636 lethal dose Toxicity 0.000 abstract description 5
- 239000012528 membrane Substances 0.000 abstract description 3
- 210000000952 spleen Anatomy 0.000 description 29
- 208000020154 Acnes Diseases 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 14
- 210000001185 bone marrow Anatomy 0.000 description 13
- 239000007924 injection Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 206010039491 Sarcoma Diseases 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000001802 infusion Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000001665 lethal effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 208000011581 secondary neoplasm Diseases 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000010322 bone marrow transplantation Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 206010024378 leukocytosis Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 101100203600 Caenorhabditis elegans sor-1 gene Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- JCYZMTMYPZHVBF-UHFFFAOYSA-N Melarsoprol Chemical compound NC1=NC(N)=NC(NC=2C=CC(=CC=2)[As]2SC(CO)CS2)=N1 JCYZMTMYPZHVBF-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241001648298 Propionivibrio Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000002358 autolytic effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000007732 propionibacterium agar Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012475 sodium chloride buffer Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000000904 thermoluminescence Methods 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3011461A DE3011461C2 (de) | 1980-03-25 | 1980-03-25 | Verwendung von Propionibakterien |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2505186A1 true FR2505186A1 (fr) | 1982-11-12 |
| FR2505186B1 FR2505186B1 (enExample) | 1984-10-12 |
Family
ID=6098254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8109265A Granted FR2505186A1 (fr) | 1980-03-25 | 1981-05-08 | Preparations a base de membranes cellulaires ou de cellules entieres de propionibacteries, utilisables notamment en cancerologie, et utilisation de propionibacteries pour obtenir ces preparations |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4647456A (enExample) |
| JP (1) | JPS57165319A (enExample) |
| AT (1) | AT371714B (enExample) |
| AU (1) | AU548596B2 (enExample) |
| BE (1) | BE888770A (enExample) |
| CA (1) | CA1197798A (enExample) |
| CH (1) | CH661868A5 (enExample) |
| DE (1) | DE3011461C2 (enExample) |
| FR (1) | FR2505186A1 (enExample) |
| GB (1) | GB2098478B (enExample) |
| NL (1) | NL189947C (enExample) |
| NO (1) | NO162079C (enExample) |
| SE (1) | SE450088B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4678773A (en) * | 1983-08-26 | 1987-07-07 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent |
| DE3817762A1 (de) * | 1988-05-26 | 1989-11-30 | Sanum Kehlbeck Gmbh & Co Kg | Immunstimulierendes mittel aus propionibakterien sowie verfahren zur herstellung desselben |
| IL101410A0 (en) * | 1992-03-29 | 1992-11-15 | Era Masis Ltd | Formulation for the treatment of cancer |
| DE19630230A1 (de) * | 1996-07-26 | 1998-01-29 | Bayer Ag | Herstellung immunstimulierender Mittel auf Basis von Propionibakterien |
| FR2764802A1 (fr) * | 1996-12-24 | 1998-12-24 | Standa Lab Sa | Composition adsorbable renfermant des bacteries propioniques susceptible de degager du monoxyde d'azote dans le tube digestif humain ou animal |
| CA2299548C (en) | 1997-08-05 | 2009-12-29 | Bioniche Inc. | Composition and method for regulating cell proliferation and cell death |
| US7709537B1 (en) * | 1999-10-19 | 2010-05-04 | Meiji Dairiese Corporation | Food materials useful in preventing and ameliorating metabolic bone diseases and preventives/remedies for metabolic bone diseases comprising these materials |
| JP4772245B2 (ja) * | 1999-12-13 | 2011-09-14 | バイオニケ ライフ サイエンシーズ インコーポレイテッド | 治療上有用な合成オリゴヌクレオチド |
| CA2395493C (en) * | 1999-12-28 | 2010-06-22 | Bioniche Life Sciences Inc. | Hyaluronic acid in the treatment of cancer |
| GB2623078B (en) * | 2022-10-03 | 2025-04-16 | Univ Brunel | Prevention and/or treatment of wound infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2269961B1 (enExample) * | 1974-05-06 | 1978-03-24 | Anvar | |
| FR2269962B1 (enExample) * | 1974-05-06 | 1978-02-03 | Anvar | |
| JPS5215894A (en) * | 1975-07-29 | 1977-02-05 | Yuichi Yamamura | Process for preparing a substance possessing biological actions |
| JPS5946206B2 (ja) * | 1975-10-08 | 1984-11-10 | （株） 目黒研究所 | 免疫学的活性を有する非病原性好気性コリネバクテリウム培養物の製造法 |
| JPS52108091A (en) * | 1976-03-03 | 1977-09-10 | Kowa Co | Production of antiitumor substance |
| JPS5411233A (en) * | 1977-06-28 | 1979-01-27 | Asahi Chem Ind Co Ltd | Anitidote |
| JPS5513204A (en) * | 1978-06-28 | 1980-01-30 | Mitsui Toatsu Chem Inc | Active compound having delayed allergic activity and anticarcinogenic activity, and its preparation |
| JPS55114290A (en) * | 1979-02-27 | 1980-09-03 | Mitsui Toatsu Chem Inc | Substance with antitumorigenic activity, its production and medical preparation |
-
1980
- 1980-03-25 DE DE3011461A patent/DE3011461C2/de not_active Expired
-
1981
- 1981-03-10 NO NO810815A patent/NO162079C/no not_active IP Right Cessation
- 1981-03-12 SE SE8101582A patent/SE450088B/sv not_active IP Right Cessation
- 1981-03-13 AT AT0118981A patent/AT371714B/de not_active IP Right Cessation
- 1981-03-24 NL NLAANVRAGE8101452,A patent/NL189947C/xx not_active IP Right Cessation
- 1981-03-27 CH CH2100/81A patent/CH661868A5/de not_active IP Right Cessation
- 1981-04-02 JP JP56050014A patent/JPS57165319A/ja active Granted
- 1981-05-06 CA CA000376972A patent/CA1197798A/en not_active Expired
- 1981-05-07 AU AU70242/81A patent/AU548596B2/en not_active Ceased
- 1981-05-08 FR FR8109265A patent/FR2505186A1/fr active Granted
- 1981-05-12 BE BE0/204763A patent/BE888770A/fr not_active IP Right Cessation
- 1981-05-15 GB GB8114915A patent/GB2098478B/en not_active Expired
-
1985
- 1985-01-03 US US06/688,278 patent/US4647456A/en not_active Expired - Lifetime
Non-Patent Citations (4)
| Title |
|---|
| CA1978 * |
| EXBK/79 * |
| EXBK/80 * |
| EXBK/81 * |
Also Published As
| Publication number | Publication date |
|---|---|
| BE888770A (fr) | 1981-11-12 |
| GB2098478A (en) | 1982-11-24 |
| ATA118981A (de) | 1982-10-15 |
| US4647456A (en) | 1987-03-03 |
| GB2098478B (en) | 1985-02-20 |
| AU7024281A (en) | 1982-11-11 |
| CH661868A5 (de) | 1987-08-31 |
| AU548596B2 (en) | 1985-12-19 |
| SE450088B (sv) | 1987-06-09 |
| FR2505186B1 (enExample) | 1984-10-12 |
| NO162079B (no) | 1989-07-24 |
| NL8101452A (nl) | 1982-10-18 |
| NO162079C (no) | 1989-11-01 |
| NL189947C (nl) | 1993-09-16 |
| DE3011461A1 (de) | 1981-10-01 |
| CA1197798A (en) | 1985-12-10 |
| JPS57165319A (en) | 1982-10-12 |
| JPH0355448B2 (enExample) | 1991-08-23 |
| NO810815L (no) | 1982-09-13 |
| AT371714B (de) | 1983-07-25 |
| NL189947B (nl) | 1993-04-16 |
| DE3011461C2 (de) | 1986-10-30 |
| SE8101582L (sv) | 1982-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kohwi et al. | Antitumor effect of Bifidobacterium infantis in mice | |
| BE1001634A4 (fr) | Vaccin contenant des antigenes de tumeurs et des adjuvants. | |
| EP0604631B1 (fr) | Utilisation d'enveloppes de bactéries de l'ordre des Beggiatoales ou du genre Vitreoscilla comme ingrédient actif d'un médicament destiné à stimuler l'immunité non-spécifique | |
| CN114540229B (zh) | 一种增强免疫检查点抑制剂治疗效应的副干酪乳杆菌株及其应用 | |
| EP0165726A2 (en) | Intestinal microflora-improving agent | |
| WO2019218401A1 (zh) | 脆弱拟杆菌或阿克曼粘细菌在制备用于预防或治疗肿瘤的药物中的应用 | |
| WO2004052462A1 (fr) | Composition comprenant des lactobacillus ou des bifidobacterium et son utilisation | |
| US5047401A (en) | Use of dipeptide alkyl esters to treat GVHD | |
| FR2505186A1 (fr) | Preparations a base de membranes cellulaires ou de cellules entieres de propionibacteries, utilisables notamment en cancerologie, et utilisation de propionibacteries pour obtenir ces preparations | |
| Davies et al. | Human protothecosis: supplementary studies | |
| EP0689842A1 (en) | Use of an organic extract of cinnamon plant to inhibit growth of helicobacter pylori | |
| EP4407023B1 (en) | Lactobacillus reuteri for prolonging lifespan, resisting aging and reducing fat, and product thereof and use thereof | |
| CN106148282A (zh) | 一种自然杀伤细胞的培养方法 | |
| CA2111564A1 (en) | Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity | |
| CN111991427A (zh) | 肠道细菌在制备用于促进TCR γδ+T细胞增殖的药物中的应用 | |
| Rogers et al. | The bacterial flora of the gut contents and environment of larval lampreys | |
| US20020115190A1 (en) | Culture of staphylococcus aureus and a method for preparing the same | |
| CN102579509B (zh) | 一种富硒安络小皮伞菌提取物制剂及其制备方法 | |
| FR2481927A1 (fr) | Composition anti-allergique et son procede de preparation a partir d'une bacterie lactique du genre streptococcus | |
| CN106884005A (zh) | 一种结直肠癌抗原特异性t细胞的制备方法 | |
| EP0199085A2 (de) | Jomol, seine Derivate, Verfahren zur Herstellung dieser Verbindungen, ihre Verwendung und Erzeugnis | |
| Kato et al. | Microbicidal activity and morphological characteristics of lung macrophages in Mycobacterium bovis BCG cell wall-induced lung granuloma in mice | |
| CN1129667C (zh) | 治疗肿瘤的自体免疫细胞及其制备方法 | |
| JPH1171297A (ja) | 癌細胞アポトーシス誘導能増強剤及び癌細胞アポトーシス誘導性組成物 | |
| CN118185812A (zh) | 一种约氏乳杆菌及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| CD | Change of name or company name | ||
| TP | Transmission of property |